Steven Cohen Vaxcyte, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $28.2 Million - $39.4 Million	-621,030 Reduced 95.37%	30,155 $1.89 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $20.8 Million - $24 Million	452,789 Added 228.22%	651,185 $33.2 Million
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $10.5 Million - $16.4 Million	-302,704 Reduced 60.41%	198,396 $9.91 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $7.2 Million - $9.37 Million	198,500 Added 65.6%	501,100 $18.8 Million
Q4 2022 Feb 14, 2023	SELL	$20.58 - $47.95 $2.47 Million - $5.76 Million	-120,200 Reduced 28.43%	302,600 $14.5 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $9.17 Million - $12.1 Million	422,800 New	422,800 $10.1 Million

290

110M

248K

109K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $6.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.